Ventures

Consult with Zoë Johnson

Head Gubra Ventures

Discuss strategic partnerships and venture opportunities.

Gubra Ventures will accelerate value creation

What is a venture?

Some opportunities are best advanced in Gubra Biotech, while others benefit from the focus, speed, and optionality that dedicated venture structures provide. A venture could encompass:

Novel modalities in therapeutic areas where Gubra has deep expertise
High value therapeutic areas leveraging modalities aligned with Gubra’s strengths, i.e. peptides
High-potential science with clear translational hypotheses

Focused venture creation aligned with Gubra’s scientific core

Why now?

Gubra Ventures reflects a deliberate evolution of Gubra’s innovation model and is based on a landscape characterised by:

Gubra’s scientific platforms and translational capabilities have reached scale and maturity
External funding increasingly favors focused, capital-efficient company models
Proven track record of trusted external partnerships
Long-term commitment to innovation and sustainable growth

A maturing platform meets a changing innovation landscape

How will Ventures accelerate value?

Gubra is uniquely positioned to evolve and differentiate our business model with Gubra Ventures through:

Earlier scientific de-risking creates stronger optionality downstream
Venture creation enables speed, focus, and flexibility without diluting our core business
Opportunities suited to focused, independent company structures
Hands-on venture stewardship with clear governance

A differentiated model built on depth, discipline, and partnership

A different model for early-stage drug development

Early-stage drug development is often limited not by the quality of the science, but by access to the infrastructure and expertise required to translate it into clinical outcomes.

Gubra Ventures was established to address this challenge.

Unlike traditional venture models, Gubra Ventures builds on an existing and proven ecosystem:
a proprietary ML-guided peptide platform, leading translational models in metabolic disease, advanced imaging capabilities, and experienced development teams with a track record of delivering clinical-stage assets and pharma partnerships.

By integrating these capabilities from the outset, we enable programmes to move forward with greater speed, scientific clarity, and reduced execution risk.

What we do

We partner with innovators to advance high-potential assets through:

In-licensing and co-development
Early-stage programme development within the Gubra ecosystem
A focus on translational strength and disciplined portfolio building

Our therapeutic focus includes obesity and metabolic disease, immunology and inflammation, and functional ageing.

Partner with us
We are actively seeking opportunities to collaborate on promising preclinical and early clinical programmes, as well as enabling technologies with strong translational potential.

“